[Oral toxicity of targeted anticancer therapies].
While toxicity of targeted anticancer therapies on the oral mucosa seems relatively frequent in clinical practice, it has not been properly characterized to date, apart from aphthous-like lesions due to mTOR inhibitors. Herein, we report the main oral lesions associated with these new therapies, with a description of the most frequent but also the most characteristic clinical manifestations of these drugs, such as anti-EGFR-induced mucositis, BRAF-inhibitor-associated hyperkeratosis, benign migratory glossitis and osteonecrosis of the jaw observed with angiogenesis inhibitors, as well as lesions more specifically linked with imatinib.
Dermatologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, institut universitaire du cancer, Toulouse Oncopole, 1, avenue Irene-Joliot-Curie, 31100 Toulouse cedex, France. Electronic address: sibaud.vincent@iuct-oncopole.fr.
V
V
Sibaud
Dermatologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, unité de dermatologie pédiatrique, hôpital Pellegrin enfants, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
F
F
Boralevi
Odontologie, consultation pluridisciplinaire de pathologie de la muqueuse buccale, institut universitaire du cancer, Toulouse Oncopole, 1, avenue Irene-Joliot-Curie, 31100 Toulouse cedex, France.
E
E
Vigarios
Unité de médecine bucco-dentaire, consultation pluridisciplinaire de pathologie de la muqueuse buccale, UFR odontologie Bordeaux, 16-20, cours de la Marne, 33076 Bordeaux cedex, France; Pôle odontologie et santé buccale, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
J-C
JC
Fricain
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D001549:Benzamides / Q000009:adverse effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005929:Glossitis, Benign Migratory / Q000139:chemically induced; D006801:Humans; D017495:Hyperpigmentation / Q000139:chemically induced; D000068877:Imatinib Mesylate; D007211:Indoles / Q000009:adverse effects; D008439:Maxillary Diseases / Q000139:chemically induced / Q000473:pathology; D058990:Molecular Targeted Therapy / Q000009:adverse effects* / Q000379:methods; D009061:Mouth Mucosa / Q000187:drug effects / Q000473:pathology; D010020:Osteonecrosis / Q000139:chemically induced / Q000473:pathology; D010879:Piperazines / Q000009:adverse effects; D047428:Protein Kinase Inhibitors / Q000009:adverse effects; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000009:adverse effects; D011758:Pyrroles / Q000009:adverse effects; D011832:Radiation Injuries / Q000150:complications; D011878:Radiotherapy / Q000009:adverse effects; D013280:Stomatitis / Q000139:chemically induced* / Q000473:pathology; D013281:Stomatitis, Aphthous / Q000139:chemically induced / Q000473:pathology; D000077210:Sunitinib; D058570:TOR Serine-Threonine Kinases / Q000009:adverse effects
D020533:Angiogenesis Inhibitors; D001549:Benzamides; D007211:Indoles; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D000068877:Imatinib Mesylate; D066246:ErbB Receptors; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D058570:TOR Serine-Threonine Kinases; D000077210:Sunitinib
Aphthous-like lesions; Benign migratory glossitis; Glossite migratrice bénigne; Hyperkeratosis; Hyperkératose; Lésions buccales; Mucite; Mucositis; Oral lesions; Osteonecrosis of the jaw; Ostéonécrose de la mâchoire; Targeted therapies; Thérapies ciblées; Ulcérations aphtoïdes